Skip to content
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’
The search for safer, effective replacements for opioids is a critical public health ...
Read More
BIF 2024: AI experts discuss use cases, benefits, ROI
“All of us have been paying attention and seeing the ‘AI high’ for ...
Read More
BIO Investor Forum panel breaks down when, what, and why of IPOs
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in ...
Read More
BIF 2024: ‘The IRA really disrupted how we think’
The Inflation Reduction Act (IRA) has been top of mind for many in ...
Read More
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health ...
Read More
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not ...
Read More
EDITORS' CHOICE
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in the ...
Read More
LATEST NEWS
BIO's View
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction Act ...
BIO Events
BIF 2024: AI experts discuss use cases, benefits, ROI
“All of us have been paying attention and seeing the ‘AI high’ for the last several years,” said Ruchita Sinha, MBA, General Partner at AV8 ...
BIO Events
BIO Investor Forum panel breaks down when, what, and why of IPOs
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the headaches, ...
BIO Events
BIF 2024: ‘The IRA really disrupted how we think’
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the impending ...
BIO's View
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve – despite ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
AGRICULTURE
Climate Change
What to know about BIO’s 7 Core Strategic Priorities
With the 118th Congress wrapping up in a few months, the Biotechnology Innovation Organization (BIO) continues its work to improve ...
Read More
Federal Policy
State Policy
Virginia Gov. Youngkin named BIO’s Governor of the Year
Virginia Gov. Glenn Youngkin on Sept. 17 received the 2024 Governor of the Year Award from the Biotechnology Innovation Organization ...
Read More
International
Bio's View
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined ...
Read More
